Attached files
| file | filename |
|---|---|
| 8-K - 8-K - Xenon Pharmaceuticals Inc. | xene-8k_20160309.htm |
EXHIBIT 99.1
|
|
Joshua P. McGinn, CEP Senior Vice President, Western Region Relationship Management
American Stock Transfer & Trust Company, LLC One Embarcadero Center – Suite 566 San Francisco, CA 94111 Office: 415.835-1313 |
March 9, 2016
|
|
|
|
Alberta Securities Commission |
|
|
British Columbia Securities Commission |
|
|
Ontario Securities Commission |
|
|
|
|
RE: Xenon Pharmaceuticals Inc.
Pursuant to a request from the above-mentioned reporting issuer, we wish to advise you of the following information in connection with its Annual Meeting of Shareholders:
|
Date of meeting: |
June 2, 2016 |
|
Record date for notice: |
April 4, 2016 |
|
Record date for voting: |
April 4, 2016 |
|
Beneficial ownership determination date: |
April 4, 2016 |
|
Securities entitled to notice: |
Common Shares |
|
Securities entitled to vote: |
Common Shares |
|
Issuer mailing directly to non objecting beneficial owners: |
No |
|
Issuer will pay for objecting beneficial owner material distribution: |
Yes |
|
Issuer using notice-and-access for registered investors: |
No |
|
Issuer using notice-and-access for non-registered investors: |
No |
|
Notice-and-access stratification criteria: |
N/A |
Yours very truly,
/s/ Joshua P. McGinn
Joshua P. McGinn
Senior Vice-President, Western Region
Relationship Management